Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dasatinib + paclitaxel + trastuzumab
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a combination therapy consisting of three agents: dasatinib, paclitaxel, and trastuzumab. Dasatinib is an orally available small molecule tyrosine kinase inhibitor that targets BCR-ABL and SRC-family kinases. Paclitaxel is a microtubule-stabilizing chemotherapeutic agent that inhibits cell division. Trastuzumab is a humanized monoclonal antibody targeting the extracellular domain of HER2/neu receptor. This triple regimen has been investigated in clinical trials for first-line treatment of HER2-positive metastatic breast cancer, particularly in patients with resistance to standard anti-HER2 therapies. The rationale for this combination stems from preclinical evidence showing synergistic effects between SRC inhibition (by dasatinib) and HER2 blockade (by trastuzumab), with added cytotoxicity from paclitaxel[1][5][6]. Clinical studies have demonstrated that this regimen can be safely administered with manageable toxicity and shows promising efficacy, including high objective response rates[1][4].
- Brand names
- Sprycel (dasatinib)Herceptin (trastuzumab)Paclitaxel (no unique brand for the combination)
- Other names
- dasatinib, paclitaxel, and trastuzumab combination
02
Targets
TUBB (Tubulin (alpha and beta subunits))ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)SFK (SRC family kinases)
Beyond the preview
Go deeper on dasatinib + paclitaxel + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dasatinib + paclitaxel + trastuzumab.